CompletedPhase 3NCT00053807
Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Pieter H. M. de Mulder, MD, PhD, MDUniversitair Medisch Centrum St. Radboud - Nijmegen
- Intervention
- aldesleukin(biological)
- Enrollment
- 96 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 1998
Study locations (17)
- Kaiser Franz Josef Hospital, Vienna, Austria
- Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium
- Universitair Ziekenhuis Gent, Ghent, Belgium
- AZ Groeninge - Campus St. Maarten, Kortrijk, Belgium
- U.Z. Gasthuisberg, Leuven, Belgium
- National Institute of Oncology, Budapest, Hungary
- Rambam Medical Center, Haifa, Israel
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy
- Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands
- Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
- Akademisch Medisch Centrum, Amsterdam, Netherlands
- University Medical Center Nijmegen, Nijmegen, Netherlands
- Daniel Den Hoed Cancer Center at Erasmus University Medical Center, Rotterdam, Netherlands
- Academisch Ziekenhuis Utrecht, Utrecht, Netherlands
- Marmara University Hospital, Istanbul, Turkey (Türkiye)
- +2 more locations on ClinicalTrials.gov
Collaborators
University of Glasgow
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00053807 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →